Patients with alkaline phosphatase that is > ULN but =< . x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within  days prior to randomization does not demonstrate metastatic disease
Evidence of metastatic breast cancer; patient considered at high risk of having disseminated disease (i.e. those with locally advanced disease, clinical N- or pathological N- with the exception of pNa in adjuvant patients) should have a CT/MRI scan of the thorax/abdomen/pelvis or any other area as clinically indicated and a bone scan or a CT scan with bone windows at any point between diagnosis of the current breast cancer and randomization to rule out metastatic breast cancer; (note PET/CT scan may be used as an alternative imaging technique and precludes the need for bone scan); patients with screening ALT/AST or ALP above institutional upper limit of normal should have liver ultrasound, CT or MRI at any time point between diagnosis of current breast cancer and randomization; screening bone scan is required if ALP and/or corrected calcium level are above the institutional upper limit; (note PET CT scan may be used as an alternative imaging technique)
Patients must have a whole body or limited whole body PET/CT scan performed within  days prior to registration
Patients with current and symptomatic pneumonitis, or extensive bilateral lung disease on high resolution CT scan
Patients able to have bronchoscopic placement of Calypso transponders as confirmed on a recent (within the past  weeks) CT scan
(For progression based solely on worsening of non-target or new, non-measurable disease) confirmation by an additional scan at least  weeks after the initial scan unless it is accompanied by correlative symptoms. In addition, all the following must hold:
There must be documentation by PET/CT scan, CT scan, or MRI, that the patient has evidence of measurable metastatic disease per RECIST ..
Patients with alkaline phosphatase that is > ULN but less than or equal to . x ULN or with unexplained bone pain are eligible for inclusion in the study if bone imaging (bone scan, PET-CT scan, or PET scan) performed within  days prior to randomization does not demonstrate metastatic disease.
No definitive evidence of metastases on screening CT or MRI of abdomen/pelvis and radionuclide whole body bone scan per the judgment of the investigator. Abdominal and/or pelvic lymph nodes measuring  cm or less in short axis diameter are allowed. Lesions identified on other imaging modalities (e.g. PSMA or choline PET) that are not visualized on CT and/or MRI or radionuclide bone scan are allowed. Equivocal lesions on bone scan should be followed up with additional imaging as clinically indicated.
Patients must have prior CT scan images available for investigators to collect
Patient has one or more metastatic tumors measurable per RECIST . by CT scan ? weeks prior to entry into the study
Appropriate diagnostic/staging workup, including:\r\n* Complete history and physical examination\r\n* Whole body PET/computed tomography (CT) scan within  days prior to study entry demonstrating hypermetabolic pulmonary lesion(s) and/or thoracic lymph node(s), with a maximum standardized uptake volume (SUV) >  for at least one lesion; if PET/CT was obtained more than  days prior to study entry and is not repeated, CT scan of the chest within  days prior to study entry demonstrating stable disease is required\r\n* Magnetic resonance imaging (MRI) of the brain or CT scan of the head with contrast within  days prior to study entry\r\n* Biopsy confirmation of suspected metastatic disease identified by PET/CT is recommended\r\n* Pulmonary function tests (PFTs) within  weeks of study entry are highly recommended but not required
Stage III A or B disease, including no distant metastases- based on following diagnostic workup:\r\n* History/physical examination prior to registration\r\n* Computed tomography (CT) scan of the chest or positron emission tomography (PET) scan within  days of study entry\r\n* CT scan of abdomen or magnetic resonance imaging (MRI) of abdomen or PET scan within  days of study entry\r\n* An MRI of the brain or head CT scan with contrast within  days of study entry\r\n* Total body PET scan within  days of study entry\r\n* Mediastinoscopies are highly recommended
Patients must have measurable disease, defined as tumor mass which is >  mm with spiral CT scan or MRI. Baseline imaging scan must be within  weeks of registration.
Bone marrow involvement based on PET/CT scan at screening
Tumor imaging and bone marrow evaluation for histologic analysis of marrow tumor cell quantity must be obtained within  weeks ( days) prior to enrollment onto study; patients must have ONE of the following:\r\n* Measurable tumor on magnetic resonance imaging (MRI), computed tomography (CT), or x-ray; measurable is defined as minimum of  mm in at least one dimension; for patients who are in first response (i.e., those patients with persistent sites of tumor after frontline therapy but who have never relapsed), a biopsy of a lesion or bone marrow must demonstrate viable neuroblastoma cells or patients must have a lesion positive on iobenguane (MIBG) scan or positron emission tomography (PET) scan; if the lesion was irradiated, the MIBG scan, PET scan or biopsy must be done at least  weeks after radiation is completed\r\n* MIBG or PET scan with positive uptake at minimum of one site; if lesion was radiated, the scan must be done at least  weeks after radiation completed\r\n* Bone marrow with tumor cells seen on routine morphology of bilateral aspirate and/or biopsy on at least one bone marrow sample
Must have presence of SSTR+ disease as documented by positive Ga--DOTATATE PET scan within  weeks of anticipated treatment\r\n* NOTE:\r\n** Positivity of Ga--DOTATATE PET scan defined as having at least one lesion that is >=  mm in diameter with uptake that is higher than or equal to liver and is qualitatively higher and distinguishable from background activity\r\n** Measurable disease as defined by RECIST .
Extensive bilateral lung disease on high-resolution computed tomography (HRCT) scan
Subject who are willing to undergo a bone marrow aspiration and biopsy and computed tomography (CT) scan for disease burden assessment
Patients must have progressive disease at study entry defined as one or more of the following three criteria that occurred while the patient was on androgen deprivation therapy; for patients enrolling on the basis of soft tissue or bone progression, the baseline scan must show progression relative to a comparison scan; if the comparison scan is not available, the baseline scan report must reference the previous scan to document progression
Patient must have documented tumor progression during or following a gemcitabine containing regimen to treat metastatic disease as established by CT or MRI scan
Participants must have shown unequivocal evidence for tumor progression by MRI or computed tomography (CT) scan
Distant metastases, based upon:\r\n* CT scan or MRI of the abdomen/pelvis within  days prior to registration and\r\n* Bone scan within  days prior to registration; if the bone scan is suspicious, a plain x-ray and/or MRI must be obtained to rule out metastasis prior to registration
No splenomegaly ? cm by CT scan.
Evidence of diverticulitis at baseline, including evidence limited to computed tomography (CT) scan only
Bone marrow involvement based on CT or PET scan at screening
MRI or CT scan of the brain must be done prior to surgery as it is considered standard of care.
Subjects who have minimal CT scan findings suspicious of residual disease are eligible provided there is no evidence of progression of disease by Rustin Criteria, defined as: \r\n* Present CT Scan findings show no change from CT Scan at baseline, and\r\n* Current CA- is below institutional upper normal limit and remains unchanged upon two consecutive measurements at least one week apart, and\r\n* CA- was above institutional upper normal limit at diagnosis
Assessment of all known disease sites, eg, by CT scan, MRI, bone scan as appropriate, and/or FDG-PET scan within  days before the first dose of cabozantinib
No distant metastases, based upon:\r\n* CT scan or MRI of the pelvis within  days prior to registration\r\n* Bone scan within  days prior to registration; if the bone scan is suspicious, a plain x-ray and/or MRI must be obtained to rule out metastasis
Equivocal bone scan findings are allowed if plain films (or CT or MRI) are negative for metastasis
Uncontrolled infections, defined as positive blood cultures within  hours of study entry, or evidence of progressive infection by imaging studies such as chest computed tomography (CT) scan within  days of registration
cT N+ or cT-T N or N+ as assessed by endorectal ultrasound (US)
Bone marrow involvement based on computed tomography (CT) or PET scan at screening
Patients are eligible if, based on the postoperative CT scan, partial breast irradiation (PBI) is judged to be technically deliverable
MRI/CT of brain within  days of lymphodepletion; CT scan of chest/abdomen/pelvis or PET/CT within  days of lymphodepletion; Exception: patients randomized to receive dendritic cells may have an MRI of the brain within  days of lymphodepletion (Turnstile II-Chemotherapy/Cell Infusion-Inclusion Criteria)
No space occupying lesion on computed tomography (CT) scan of the liver i.e. normal CT scan post-resection; small lesion in the liver after resection can be ablated by alcohol injection or radio frequency ablation and can make patient eligible
Presence of metastatic disease is not allowed; subjects must be evaluated with imaging consisting of CT scan and PET scan prior to enrollment for protocol therapy to exclude metastatic disease
Colonoscopy(or CT colonogram(within  months prior to randomization)
Subjects must not have evidence of pneumonitis or inflammatory lung disease on CT scan and x-ray
Computed tomography (CT) scan and MRI of the pelvis within  days prior to enrollment (note: [a] if patient has medical contraindication to MRI, an exemption will be granted and enrollment can proceed [b] for patients with PSA < . ng/mL, the treatment planning CT can substitute for a diagnostic CT scan)
Bone scan within  days prior to enrollment; if the bone scan is suspicious, a plain x?ray and/or MRI must\r\nbe obtained to rule out metastasis, and advanced imaging (e.g., NaF positron emission tomography [PET]/CT) is strongly recommended
Resective surgery within  months prior to the initial pre-treatment AMT-PET scan
Participants must have shown unequivocal evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan\r\n* For Cohort  subjects, CT or MRI within  days prior to study registration; for Cohort , corticosteroid dose must be stable or decreasing for at least  days prior to the scan; if steroids are added or the steroid dose is increased between the date of the screening MRI or CT scan and the start of treatment, a new baseline MRI or CT is required\r\n* For Cohort  subjects, CT or MRI should be performed ideally within  days prior to study registration, it is acceptable for this MRI/CT to have been performed greater than  days prior to registration if unavoidable; furthermore, fluctuation in corticosteroid dose around this MRI does not warrant repeat scan so long as there is documented unequivocal evidence of tumor progression available
Patients with alkaline phosphatase that is > ULN but =< . x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within  weeks prior to randomization does not demonstrate metastatic disease
Patients must have baseline PET scan within  days prior to registration; note that images are submitted centrally for review
One or more tumors measurable on CT scan/MRI scan per RECIST v .. - Previously irradiated tumors may be eligible if they have clearly progressed in size.
Participants must have histologically or cytologically confirmed invasive squamous, basaloid, or cloacogenic carcinoma of the anal canal; pathology must be reviewed by the treating institution; patients must be clinically staged as T stage - and N-N stage, based upon the following minimum diagnostic work-up:\r\n* History/physical examination within  days prior to registration\r\n* Anal examination with mandatory biopsy and any of the following: colonoscopy, sigmoidoscopy, rigid proctoscopy, or anoscopy; digital rectal examination (performed at the discretion of the treating physician) with documentation of primary anal lesion size, distance from the anal verge, and anal tone is also recommended\r\n* Groin examination with documentation of any groin adenopathy and lymphadenopathy (location: right vs. left, medial vs. lateral, mobile vs. fixed, and size)\r\n* A biopsy is not needed for pathologically enlarged or clinically suspicious inguinal, perirectal, or pelvic lymph nodes on examination, computed tomography (CT) scan, or positron emission tomography (PET)/CT and will be considered clinically positive\r\n* No evidence of distant metastatic disease as determined by CT scan with contrast, or PET/CT scan of the chest within  days prior to registration and CT scan with contrast, magnetic resonance imaging (MRI), or PET/CT of the abdomen and pelvis within  days prior to registration
Pretreatment evaluations required for eligibility include:\r\n* A medical history, physical examination, assessment of Zubrod performance status within  weeks prior to study entry;\r\n* Complete blood count (CBC) with differential and platelet count, and laboratory profile must be completed within  weeks prior to study entry;\r\n* FEV, CT scan or magnetic resonance imaging (MRI) of the chest, a bone scan (or positron emission tomography [PET] or PET/CT), and a CT scan or MRI of the brain (to rule out brain metastasis) within  weeks prior to study entry;\r\n* Medical Oncology and Radiation Oncology consults and approval
Patients must have a chest CT scan, or PET/CT scan to rule out metastatic disease
CT scan or Ultrasound-based volume estimation of prostate gland ?  grams;
CT scan that demonstrates no evidence of disease (NED) after completion of adjuvant therapy Note: This CT scan will also be used for Texture analysis.
PET/CT scan to include both lungs, the mediastinum, and adrenal glands; primary tumor dimension will be measured on diagnostic CT and again on simulation CT; must be done within  weeks prior to study entry
Patients with history of second malignancy are eligible if they have documentation of disease stability, off therapy, based on computed tomography (CT) scan or other measures for the  months prior to entry in core
Patients with radiographic evidence of metastatic prostate cancer (stage M or D). Distant metastases evaluable by radionuclide bone scan, CT scan, or MRI within  days before the start of study treatment.
Evidence of diverticulitis at baseline, including evidence limited to computed tomography (CT) scan only
Bone marrow involvement based on CT or PET scan at screening
Participants must have a progression by MRI or computed tomography (CT) scan; a scan must be performed within  days prior to cycle , day  (Cd) and on a steroid dose that has been stable for at least  days; if the steroid dose is increased between the date of imaging and Cd, a new baseline MRI/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement; a patient who develops a contraindication to undergo an MRI scan during study treatment may remain on study and undergo contrast enhanced CT scans
Subject has evidence of pre-existing idiopathic pulmonary fibrosis on computed tomography (CT) scan at baseline
DCFPyL-PET/MRI or DCFPyL-PET/CT scan within the past  months with results that demonstrate more disease lesions than baseline CT/bone scan
Standard staging exams for patients with high-risk prostate cancer including bone scan or sodium fluoride (NaF) positron emission tomography (PET)/CT scan, and pelvic and prostate MRI
Patients should undergo a repeat MRI prior to enrollment if there is a significant worsening or new neurologic symptoms in the interval between the eligibility scan and start of protocol therapy\r\n* The repeat scan will act as a new baseline and the eligibility scan for these patients
CT or MRI within  days prior to start of study drug; MRIs should include vascular imaging when possible; corticosteroid dose must be stable or decreasing for at least  days prior to the scan; if steroids are added or the steroid dose is increased between the date of the screening MRI or CT scan and the start of treatment, a new baseline MRI or CT is required
Participants having undergone recent resection of recurrent or progressive tumor will be eligible as long as the following conditions apply:\r\n* They have recovered from the effects of surgery\r\n* Residual disease following resection of recurrent tumor is not mandated for eligibility; to best assess the extent of residual disease post-operatively, an MRI or CT scan should be done no later than  hours following surgery or at least  weeks post-operatively, in either case within  days prior to start of study drug; if the participant is taking corticosteroids, the dose must be stable or decreasing for at least  days prior to the scan; if steroids are added or the steroid dose is increased between the date of the screening MRI or CT scan and the start of treatment, a new baseline MRI or CT is required
Patients with a history of pulmonary disease or findings present on baseline high-resolution chest CT scan that, in the opinion of the treating investigator, would put the patient at risk of complications of pneumonitis will be excluded
An MRI/CT scan showing progression is required; stable corticosteroids are not required
Detectable metastases by bone scan, CT-scan or MRI
PET/CT or CT-scan of the neck showing no evidence of nodal involvement
There must be documentation by PET/CT scan, CT scan, or MRI, that the patient has evidence of measurable metastatic disease per RECIST criteria.
Patients must have shown unequivocal radiographic evidence for tumor progression by MRI or CT scan; a scan should be performed within  days prior to registration and on a steroid dose that has been stable or decreasing for at least  days; if the steroid dose is increased between the date of imaging and registration a new baseline MR/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement
No evidence of regional nodal or distant metastases based on computed tomography (CT) abdomen and pelvis and whole body bone scan within  days prior to study entry; nodes less than . cm will be considered reactive and biopsy is not required; nodes . cm or larger are required to undergo biopsy and be negative prior to study registration; bone scan findings in the absence of blastic or lytic lesion correlates on CT imaging will also be deemed non-neoplastic
Indicator lesion that has uptake of mTc-MDP on bone scan or a Sodium Fluoride ( Na F) Bone PET scan and can be subjected to quantitative assessment by this scans and possibly other means.
REGISTRATION EXCLUSION CRITERIA: Evidence of distant metastasis present by CT scan, bone scan, or physical exam
Participants must not have metastatic disease; pre-operative chest CT scan is required within  weeks prior to registration; patients with overt evidence of lung metastatic disease are excluded from the study; however, because of the sensitivity/specificity of the chest CT, small incidental lesions without a histologic diagnosis may not be a basis for study exclusion
Patients cannot have known hepatic or peritoneal metastases detected by ultrasound (US), CT scan, MRI or laparotomy
Glioma showing prior spontaneous hemorrhage as determined from the clinical history or from any preoperative computed tomography (CT) or MRI scan (excluding grade  punctate, incidentally found)
Patients must not have evidence of bone metastases or lymph node involvement as determined by bone scan or computed tomography (CT) scan of the abdomen and pelvis within  weeks of study entry; Note: NaF-PET/CT scan information will NOT be used to determine evidence of metastases for eligibility purposes or for defining disease progression
Baseline mammography prior to surgery is required; for patients with lymphatic involvement computed tomography (CT) scan of the chest, CT of the abdomen, and bone scan and/or positron emission tomography (PET)/CT scan are required prior to delivery of chemotherapy; for most patients, this will be months prior to radiation; for patients with low burden nodal disease only mammography prior to surgery will be required\r\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Patients must have an unequivocal progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan; a scan must be performed within  days prior to registration and on a steroid dose that has been stable or decreasing for at least  days; if the steroid dose is increased between the date of imaging and first dose of plerixafor, a new baseline MRI/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement; a patient who develops a contraindication to undergo an MRI scan during study treatment may remain on study and undergo contrast enhanced CT scans
These laboratory values must be obtained within  days prior to registration; patients with levels of one or more of these enzymes greater than institutional upper limit of normal (IULN) may still be enrolled if metastatic disease is excluded with appropriate imaging which may include dedicated liver imaging, bone scan, PET, CT, MRI, or biopsy when appropriate
Patients may have had one cycle only of ABVD prior to enrolling on study; no other prior treatment (chemotherapy or radiation therapy) for Hodgkin lymphoma is allowed; if patient has had one cycle of ABVD, in order to be eligible to enroll on Cancer and Leukemia Group B (CALGB) , the patient must have had all of the following tests prior to starting the first cycle of ABVD:\r\n* Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multi gated acquisition (MUGA)\r\n* Pulmonary function tests (PFTs) (including diffusing capacity of the lung for carbon monoxide [DLCO]/forced vital capacity [FVC])\r\n* CT scan (neck**, chest, abdomen, pelvis)\r\n* FDG-PET/CT scan\r\n* Chest X-ray, posterior-anterior (PA) & lateral\r\n* Complete blood count (CBC), differential, platelets\r\n* Erythrocyte sedimentation rate (ESR)\r\n* Serum creatinine\r\n* Glucose\r\n* Aspartate aminotransferase (AST)\r\n* Alkaline phosphatase\r\n* Bilirubin\r\n* Lactate dehydrogenase (LDH)\r\n** Patients with a negative FDG-PET/CT scan do not need to have had a dedicated neck CT scan prior to starting the previous cycle of ABVD
No evidence of locoregional disease or distant metastases at screening. Subjects must have negative scans (CT, CT-PET or MRI) for locoregional recurrence, brain or lung metastases. A negative biopsy will be mandated in patients with a positive scan. Other evaluations should be performed as clinically indicated.
No other signs of clinical recurrence or dissemination of prostate cancer as defined by normal CT-scan or MRI of the pelvis without local recurrence, and bone scan negative for metastases, and chest X-ray negative for metastases; prostascint scans will not be used to assess disease prior to study entry
History of diverticulitis (even a single episode) or evidence of diverticulitis at baseline, including evidence limited to computed tomography (CT) scan only; note: diverticulosis is not an exclusion criterion per se
Histologically proven adenocarcinoma of the prostate with evidence for skeletal metastases on bone scan and/or CT scan.
Use of drugs to treat or prevent herpesvirus infections, including ganciclovir, acyclovir, valacyclovir, valganciclovir, foscarnet, cidofovir, and adefovir, must be stopped >=  hours prior to the baseline [I]FIAU-PET-CT scan and cannot be resumed until after the last [I]FIAU-PET-CT scan
Tumor is not clearly shown on a computed tomography (CT) scan
Uneqivocal evidence of a first tumor recurrence or progression on the initial treatment regimen (prior to enrollment on this study), consisting of surgical intervention (biopsy and/or resection), radiation, and temozolomide chemotherapy, as assessed by MRI or CT scan of the brain with or without contrast within  days prior to the start of SL-. If receiving corticosteroids, the dose must be stable or decreasing for at least  days prior to the scan. Patients unable to undergo MRI because of non-compatible devices can be enrolled, provided CT scans are obtained and are of sufficient quality. For each patient, the same imaging technique should be performed throughout the study, for purposes of assessing tumor response or PD.
A baseline scan should be performed within  days prior to registration and on a steroid dosage that has been stable for at least  days otherwise a new baseline MR/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement
All patients must have undergone staging of their lung cancer prior to enrollment with a chest CT scan and PET scan, both within  weeks of inclusion, in addition to bronchoscopy
Patients that undergo bronchoscopy and are found to have endobronchial lung cancer that is obstructive or hemorrhagic as evident by inspection or CT scan are eligible
Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with computed tomography (CT) scan, as >=  mm by chest x-ray, or >=  mm with calipers by clinical exam; PET/CT scan is acceptable as a substitute for a CT scan if the CT portion of the PET/CT is of identical diagnostic quality to a diagnostic CT scan
CT scan chest, abdomen and pelvis or positron emission tomography (PET)/CT scan (diagnostic quality CT) performed within  days of study registration; for disease outside the brain, tumors must be >  mm by CT scan
D CT positive for multiple gland disease
Chest radiograph or computed tomography (CT) scan within =<  months prior to study enrollment rules out primary or metastatic malignancy in the lungs or pleural space as a significant cause of respiratory insufficiency
Uncontrolled infections, defined as positive blood cultures within  hours of study entry, or evidence of progressive infection by imaging studies such as chest computed tomography (CT) scan within  days of registration
Inability to tolerate po; patients who have a computed tomography (CT) scan with contrast dye within  days and/or have a pacemaker will be excluded from having a dual energy x-ray absorptiometry (DEXA) scan only
Cytotoxic chemotherapy within  weeks of first planned study PET/CT scan
Filgrastim (G-CSF) therapy within  days of the first planned research PET/CT scan
Computed tomography (CT) scan of the chest done =<  months prior to pre?registration showing either negative findings (no nodules) or solid or part?solid nodules <  mm in size (consistent with < % probability of malignancy, Lung?Reporting and Data Systems [RADs] version .)
Willing and able to undergo low dose computed tomography (CT) scan, as determined by radiology team, or has had a lung cancer screen within  days of enrollment into this protocol.
All nodules should be persistent at least after three months follow up with  dimension (d)-CT; a reduction up to % of the diameter of the largest target nodule from the previous CT scan is allowed
Patient must be able to lie still for a - minute PET/CT scan
Radiologic evidence of local recurrence or new or progressive metastatic disease demonstrated on anatomical imaging (CT, MRI, or ultrasound), whole-body bone scan (m-Tc-MDP or Na-F) within  weeks of enrollment.
Negative technetium -m methylene diphosphonate (MDP) or F- PET bone scan for skeletal metastasis
Eligibility of a perfusion CT target lesion must be confirmed by the ACR Core Lab prior to study enrollment and the T perfusion CT scan
Any change in prostate cancer treatment between Axumin and Ga-PSMA PET/CT scan
Patient must be able to lie still for a  to  minute PET/CT scan
SUB-STUDY III: Imaging evidence of suspected metastatic disease, including CT, bone scan, MRI, ultrasound or other PET modalities
Able to remain motionless for up to - minutes per scan
Serum total bilirubin =< . x ULN, obtained within  days prior to C-AMT PET scan
Adjuvant anticancer treatments are allowed if at least  days has elapsed between the infusion/injection and C-AMT PET scan as part of this study
Patient must be able to lie still for a  to  minute PET/CT scan.
Subjects must have a computed tomography (CT) scan of the chest within  weeks of surgery
No evidence of metastatic disease on conventional imaging, including a negative bone scan for skeletal metastasis and negative contrast-enhanced CT; sodium fluoride (NaF) PET CT can substitute for separate bone scan and CT
Inability to undergo or cooperate with PET/computed tomography (CT) scan (e.g., claustrophobia)
The patient must provide informed written consent, which will include a laymans explanation of the estimated amount of additional radiation that the patient will receive from the investigational PET/CT scan using F-FSPG
Peptide receptor radionuclide therapy (PRRT) within  weeks of Ga- DOTATOC PET/CT scan
Able to have bronchoscopic placement of Calypso transponders as confirmed on a recent (within the past  weeks) CT scan
Study subjects will have undergone or are scheduled for PET-CT and/or bone scan within about  weeks of the WB and primary tumor DWI MRI
Evidence of stroke or mass lesion on CT or MRI scan
Able to cooperate for the PET CT scan when registered on study
Patients who have started radiographic evaluation and underwent CT scan and/or bone scan prior to registration to the study will be able to participate under a late registration provision, provided that the more modern scans (WB/axial MRI and F- NaF PET/CT) can be completed within  weeks after CT scan and bone scan
Pregnant or lactating female, a serum pregnancy test will be performed within  weeks or less before the date of the FCH PET/CT scan in all women capable of becoming pregnant
Patients must have evaluable disease by CT scan
Patients undergoing a planning CT scan in the Department of Radiation Oncology with tumor motion assessment - planning -dimensional (D)-CT ordered by the treating radiation oncologist
All pathology specimens must be within  year of the planned F-FSPG PET/CT scan.
Metastatic workup\r\n* Whole body sodium fluoride (NaF) PET/(CT) computed tomography or mTc bone scan
Pretreatment evaluations required for eligibility include:\r\n* A medical history, physical examination, weight, assessment of ECOG performance status within  weeks prior to study entry;\r\n* Evaluation by an experienced thoracic cancer clinician within  weeks prior to study entry;\r\n* For women of childbearing potential, a serum or urine pregnancy test must be performed within  hours prior to the start of protocol treatment;\r\n* CT scan (preferably with intravenous contrast, unless medically contraindicated) to include the entirety of both lungs, the mediastinum, liver, and adrenal glands; primary tumor dimension will be measured on CT;\r\n* Whole body positron emission tomography (PET)/CT scan using fludeoxyglucose (FDG)- with adequate visualization of the primary tumor and draining lymph node basins in the hilar and mediastinal regions; \r\n* Ability to understand and the willingness to sign written informed consent document
Evidence of metastatic disease demonstrated by an abnormal bone scan, CT scan, MRI and/or FDG-PET scan within  weeks (with no further interval treatment before imaging trial)
Participant is scheduled for standard clinical and/or investigational PET/CT scan or  I therapy within the Nuclear Medicine Service at Main Hospital
Radiation treatment to bone less than  weeks from the first PET scan
Radiopharmaceutical treatment to bone less than  weeks from first PET scan
Had a chest computed tomography (CT) scan within the past  months prior to enrollment
Patients for whom the physician is able to identify suitable implantation sites for the anchored transponders on a recent (within the past  weeks) CT scan. This will require acquisition of a CT scan if a suitable one is not already available.
